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Abstract
Objectives Many traditionally established medical inter-
ventions are not examined with randomized trials espe-
cially in emergency medicine. We researched what is the
scientific basis of the measurement of the causal effect in
these interventions and proposed another trial to measure
causal effects.
Methods We deduced steady state trials from the coun-
terfactual model and used Bayesian approaches to estimate
causal effects statistically.
Results When the state of the observed person is fairly
steady before an exposure, the ratio of the after-period to
the before-period of the exposure is sufficiently small, and
changes are obtained in relatively short time, it is possible
to postulate that the state of the counterfactual person to be
compared is almost equal to the state of the real person
before the exposure. Bayesian approaches show that the
causal effect of the exposure is estimated even in only one-
person steady state trials, when large changes are observed.
Conclusions Steady state trials are valid methods to
measure causal effects and can measure causal effects even
in one-person trials. When we can measure the causal
effect of interventions with steady state trials, these inter-
ventions should be regarded as scientific without use of
randomized trials.
Keywords Cross-over trials  Counterfactual model 
Steady state  Period ratio  Individual causal effect
Introduction
Evidence-based medicine (EBM) appeared as a handy tool
kit for clinicians who had not understood the basic thinking
of epidemiology [1]. After the advocates of EBM suc-
ceeded in nominating randomized trials to be paramount
[2], the so-called ‘‘Hierarchy of Strength of Evidence’’
towered in medical practice and many clinical guidelines
prostrated themselves in front of the pyramid [3, 4]. Many
traditionally established medical interventions were strip-
ped of their rank for reasons having to do with observa-
tional studies. Under these circumstances, Smith and Pell
[5] asked a sarcastic question why protagonists of EBM did
not participate in a randomized trial of parachute use.
In epidemiological studies, the counterfactual or poten-
tial-outcome model has become increasingly standard for
causal inference [6–8]. However, the theoretical ideal to
measure causal effects of exposure is impossible. To
achieve a valid substitution for the counterfactual experi-
ence, we resort to various design methods that promote
comparability. One approach is a cross-over study and
another is a randomized trial. Other approaches might
involve choosing unexposed study subjects who have the
same or similar risk-factor profiles for disease as the
exposed subjects [9]. Case-crossover design was intro-
duced for estimating a short term, transient effect of
intermittent exposures on acute-onset diseases [10, 11]. For
The primitive idea was presented by OI in the lecture ‘‘From
evidence-based medicine to scientific medicine’’ at the 42nd biannual
meeting of Department of Neurology, Kyoto University Graduate
School of Medicine in December 2011.
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each case, one or more predisease or postdisease time periods
are selected as matched control periods for the case. The
exposure status of the case at the time of the disease onset is
compared with the distribution of exposure status for the
same person in the control periods. The key feature of the
case-crossover design is that each case serves as its own
control. In this paper, we expand this key feature and propose
another valid substitution of the counterfactual ideal to
measure causal effects and show that parachute use and many
interventions in emergency medicine have the scientific basis
of the causal inference without randomized trials.
Materials and methods
We deduce steady state trials from the counterfactual model.
The scheme is presented in Fig. 1. Bayesian methods are used
to estimate causal effects statistically [12, 13] (see appendix).
Posterior distributions are computed with WinBUGS version
1.4.3, which reports two-sided equi-tail-area credible inter-
vals [14]. We use these intervals for convenience, although
highest posterior density intervals are more preferable.
Results
Steady state trials
For the purpose of discussion, letters are defined as
follows;
t time
T0 the time when the observation starts
T1 the time when the exposure is done
T2 the time when the outcome is observed
B = (T1 - T0) the period before the exposure
A = (T2 - T1) the period after the exposure
n the integer which gives the ratio of A to
B, A:B = 1:n
S the state of the observed person which is
a function of time
X the state S just before the time T1
Y the state S at the time T2
Z the state of the counterfactual ideal of the
unexposed person which is a function of
time
W the state Z at the time T2.
Steady state trials begin with the observation of the state
of the object person (Fig. 2). Suppose the state is almost
steady during the period B (Fig. 3). Namely, the derivative
of the state with respect to time during the period B is
dS
dt
¼ k þ d;
where k is a constant and d is noise which follows the
normal distribution N(0, r2). We observe the state S
(n ? 1)-times at the interval of the period A and obtain
sample noises n-times (di; i = 1, 2,…, n) during the period
B. Just before the exposure, the state is recorded as X.
When we observe Y at the end of the period A after the
exposure, we get the mean value of dS
dt during the period A:
dS
dt
¼ ðY  XÞ=A:
When the ratio of the period A to the period B is suffi-
ciently small, i.e., n is sufficiently large, we can postulate
the derivative of the counterfactual unexposed state is k
plus noise dz which follows the same distribution as dis:
dZ
dt
¼ k þ dz:
However, we cannot really observe dZ
dt , so the value of
(k ? dz) is replaced with the observed value of (k ? dis).
In order to estimate the difference between (Y –X)/A and
(k ? dis), we postulate that the distribution of (Y – X)/
A follows the normal distribution with the same variance as
r2 which is estimated by the sample variance of (k ? dis).
Then the difference between (Y – X)/A and (k ? dis) can be
statistically estimated with the t distribution. When the
outcome Y has the quality different from the state X, the
nominal scale is applied.
Fig. 1 Counterfactual model. We establish a hypothetical person in
the counterfactual world in order to compare the outcome of the
exposed person with the outcome of the unexposed person. After
the exposure, both the conditions of the exposed person and the
unexposed person are observed at the same time. As the only
difference between the two settings is the exposure, it is possible to
measure the effect of the exposure
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Statistical inference of causal effects
Suppose when we observe the outcome Y which belongs to
the category different from the state X and the change is
of practical importance, or when the difference between
(Y – X)/A and (k ? dis) is statistically significant and large
enough to be of practical importance. We now discuss the
causation of the incidence of such an important outcome Y,
which we designate Yimp in the following discussion.
The probability that Yimp happens during the period A
with the exposure is represented by the letter he:
he ¼ PðYimp jE; CÞ;
where E is the exposure, C is the condition that the state is
steady during the period B and the vertical line represents
conditioning. We postulate that Yimp is a Bernoulli variable
during the period A. The probability that Yimp happens
during the period A without the exposure (:E) is
represented by the letter hu:
hu ¼ PðYimp j :E; CÞ:
As the state is steady and the period A is small relative to
the period B, we can postulate that the counterfactual
condition of the unexposed state in the period A is
equivalent to the real condition in the period B, and the
probability that Yimp happens within the time span of the
period A during the period B is equal to hu. Then the period
B has a sequence of n-times repetitions of a trial with
constant probability hu.
Suppose that we observe Yimp after the exposure and
there is no incidence of Yimp during the period B in one
steady state trial. The components of the Bayesian model
for steady state trials can be written as follows:
prior distribution he  Beta a1; b1ð Þ
hu  Beta a2; b2ð Þ
likelihood p yejheð Þ ¼ he
p yujhuð Þ ¼ 1  huð Þn
posterior distribution D ¼ he ye  huj jyu;
,where ye is the success of Yimp in one trial under the
exposure, yu is the no success of Yimp in n trials under the
non-exposure, and D is the difference between he and hu
taking account of the trial evidence. Ideally, the likeli-
hood of no success under the non-exposure should be
computed with n-times trials in the real world and one-
time trial in the counterfactual world. The trial in the
counterfactual world cannot be observed. Thus, we
approximately compute this likelihood with n-times trials
in the real world. The posterior distribution D is computed
with WinBUGS.
When we are uncertain about the prior distribution, we
adopt Beta(0.5, 0.5) or Beta(1, 1) as the reference prior
distribution for he and hu. The posterior distribution of hu
shifts to zero as n becomes larger. With the reference prior
Beta(0.5, 0.5) for he and hu, the lower limit of the 95 %
credible interval of D is over zero when n is equal to or
more than four. With the reference prior Beta(1, 1) for he
and hu, the lower limit of the 95 % credible interval of D is
over zero when n is equal to or more than seven. Classical
statistical approaches also show similar results [15, 16].
The larger the number of n is, the more credibility we can
gain in the inference of the causal effect. However, the
lower limit of the 95 % credible interval of D cannot be
over 0.15 with the prior Beta(0.5, 0.5) and not over 0.16
with the prior Beta(1, 1), no matter how n may become
large. This is the limitation of one-person trials. Population
studies with many persons can show larger lower limits of
the credible interval, if the success proportion is high.
Fig. 2 Steady state trials. S the state, X S just before the exposure,
Y S at the end of the period A, W the counterfactual state at the end of
the period A. S is steady during the period B
Fig. 3 Derivative of the state. Period A:Period B = 1:n, where n is a
positive integer. dS
dt is the derivative of S with respect to time;
dS
dt = k ? d, where k is constant and d (di; i = 1, 2,…, n) is noise
which follows the normal distribution. We observe the state (n ? 1)-
times at the interval of the period A during the period B. The
counterfactual derivative of the state is postulated as (k ? dz), where
dz follows the same distribution as dis
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Steady state implies that the previous observations of the
same condition showed no incidence of Yimp without
the exposure. When we believe the previous evidence for
the no-incidence of Yimp under the non-exposure, we can
adopt, for example, Beta(1, 1000000) as the prior distri-
bution for hu. Adopting almost null prior distribution
Beta(1, 1000000) for hu means that p(D) is practically
equal to p(he|ye).
Relation to cross-over trials
The simple cross-over design is outlined by Armitage et al.
[17]. With two treatments, F and G, one randomly chosen
group of patients receives treatments in the order FG, while
the other group receives them in the order GF. The active
response that is common to all subjects in a particular
group and particular period with the treatment received is
modeled as follows:
Period 1 Period 2
Group I (FG) l ? sF ? p1 l ? sG ? p2 ? cFG
Group II (GF) l ? sG ? p1 l ? sF ? p2 ? cGF
Here, l is a general mean, the s terms represent treat-
ment effects, the p terms represent period effects, and the c
terms represent the treatment 9 period interaction.
When F is no treatment, sF and cFG are null and the
model of the group I is as follows:
Period 1 Period 2
Group I (FG) l ? p1 l ? sG ? p2
Suppose the ratio of the period 2 to the period 1 is 1:n.
The constancy of dS
dt means that the period effect p1 is
constant during the period 1. Under the condition of state
steadiness which is confirmed by the (n ? 1) times
observations during the period 1, when the period 2 follows
successively the period 1 and n is sufficiently large, we can
postulate that the p2 is almost equal to (p1 ? p1/n) in the
group I. The larger n is, the more we can believe the
steadiness of the state and the approximation of p2. Then
the difference of the response between the two periods is
(sG ? p1/n) and we can measure sG with the repeated
observations of group I. Thus steady state trials are con-
sidered as variants of cross-over trials.
Prerequisite for steady state trials
How many figures should we adopt for n? In the above
model, we postulate that dZ
dt is equal to k, or p2 is equal to
(p1 ? p1/n). When n is infinitely large, this postulation is
reasonable. However, when n is moderately large, the
postulation receives criticism. There are many biological
parameters which show cyclical or periodic variations, for
example follicle-stimulating hormone or luteinizing hor-
mone levels in female blood plasma. Another criticism is
that the observed variable might reach the critical point
after the steady state and change drastically without
exposures. Before executing steady state trials in medicine,
we have to examine biologically the trial condition for the
possibility of cyclical or drastic state change. If some
period ratio is thought to be critical, we have to avoid using
such n for steady state trials.
Discussion
We have deduced steady state trials (SSTs) from the
counterfactual model, from which randomized controlled
trials (RCTs) were also deduced. Although RCTs are
thought to be paramount trials in recent clinical research,
STTs can also offer the valid method to measure causal
effects, when the state before the exposure is steady and
large changes are immediately observed. The smaller the
ratio of the after-period to the before-period is, the better
we can rely on the measurement of the causal effect. When
the after-period is relatively long, the measurements of
SSTs may be confounded and RCTs should be considered
in such situations. RCTs are also necessary when outcomes
long after the exposure are important, even if SSTs show
causal effects immediately.
Individual causal effects are defined as a contrast of the
counterfactual outcomes. Because only one of those values
is observed, it has been proposed that individual causal
effects cannot be identified in epidemiological research
[18, 19]. The epidemiologic principle is that a person may
be exposed to an agent and then develop disease without
there being any causal connection between exposure and
disease [9]. SSTs show that we can measure individual
causal effects in the condition where repeated observations
are performed, the state before the exposure is steady, and
large changes are immediately obtained after the exposure.
This approach could open the door to the individual causal
inference and other conditions for the individual causation
that should be researched in epidemiology.
One example of steady state trials is parachute use in
skydiving [5]. At the height of 4000 m, we jump into the
sky and we are falling at the terminal velocity of 55 m/s
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after a few seconds. Within 3 s after opening parachutes,
we usually fall at the next terminal velocity of 5 m/s. Now
we record acceleration values at the interval of 3 s. Once
we have the terminal velocity of 55 m/s, the acceleration
value of 0 m/s2 is observed about twenty times before
opening parachutes and the deceleration value of 17 m/s2
for 3 s is observed one time after opening parachutes. The
Yimp is the deceleration value of 17 m/s
2 for 3 s. After
sampling one successful skydiving, the 95 % credible
interval of the posterior distribution D with prior Beta(0.5,
0.5) is computed as 0.12–0.99. In 2010, 1308 members of
the United States Parachute Association (USPA) reported
skydiving injuries requiring medical attention [20]. During
the same year, USPA members and first-time students
made roughly 3 million jumps. These data may be trans-
lated into the following sample distribution.
Under the exposure 2998692 Yimps out of 3000000 trials
Under the non-exposure No Yimp out of 3000000  20 trials
We adopt Beta(0.5, 0.5) as the prior distributions for he
and hu. However, the huge sample size fixes practically the
same posterior distribution as when we believe the prior
probability of hu is almost null. The 95 % credible interval
of D is computed as 0.9995–0.9996 with WinBUGS.
Classical statistics show that the 95 % confidence interval
of the safe skydiving proportion is 0.99954–0.99959.
SSTs are practicable in the situation where immediate
clinical responses are important, such as in the emergency
room, where confounders are under the control of practi-
tioners. Many treatments in emergency medicine have a
long good history of SSTs in innumerable persons and can
be regarded as scientific medical interventions without
RCTs, such as intravenous injection of glucose for patients
in hypoglycemic coma, injection of adrenalin (epinephrine)
for patients with anaphylactic shock, a tourniquet for
bleeding patients, and so on.
For example, one-person SST is presented in the use of
adrenalin injection for an imaginary adult patient with
anaphylactic shock. The data of the patient is shown in the
Table 1. The systolic blood pressures (SBP) were recorded
at the interval of 1 min. The patient had an intravenous
injection of 0.1 mg adrenalin at time 10 min. We first
check whether dS
dt in the period B follows normal distribu-
tion. If there are any outliers, SSTs is not the choice for this
trial. The data of the table can be considered as following
normal distribution. The mean of (k ? dis) is one. The
estimated variance of (k ? dis) is
[(-1)2 ? (-2)2 ? 02 ? 22 ?
(-1)2 ? 02 ? 12 ? 02 ? 02 ? 12]/(10 - 1) = 1.33.
The standard error of [(Y - X)/A - (k ? dis)] is
H[1.33(1/1 ? 1/10)] = 1.21.
Two-sample t statistic is (32 - 1)/1.21 = 25.6,
which follows the t distribution on (1 ? 10 - 2) = 9
degrees of freedom. The P value is computed as\10-8. In
this statistical estimation, we postulate that the distribution of
(Y – X)/A follows the normal distribution with the same
variance as r2 which is estimated by the sample variance of
(k ? dis). However, we do not really have data for the esti-
mation of the variance of (Y – X)/A. We propose the above P
value as an informal index to be used as a measure of dis-
crepancy between (Y – X)/A and (k ? dis). We recommend
that this P value should be smaller than 0.001 to show dis-
crepancy. SBP over 90 mmHg is a clinically important value
in shock, and we can consider that dS
dt of 32 mmHg/min for
1 min after the exposure is Yimp. With prior Beta(0.5, 0.5) for
he and hu, the 95 % credible interval of the posterior distri-
bution D is computed as 0.09–0.99. When we have the prior
information that Yimp have not been observed in the past
unexposed states for 1000 min in total, we can adopt
Beta(0.5, 1000.5) as the prior distribution for hu and n can be
smaller to infer causal effects, if we confirm that unexposed
state in the period B is in the same condition as the previously
reported unexposed states. After observing one success of
Yimp after the exposure, with prior Beta(0.5, 0.5) for he, prior
Beta(0.5, 1000.5) for hu and n = 1, the 95 % credible
interval of the posterior distribution D is computed as
0.15–1.00. Practically, n will be more than two in order to
confirm the equal conditions, even when we adopt almost null
prior for hu. When we execute SSTs in population studies, if
some period ratio is thought to be critical, the participants are
divided into two or three groups to which different values of
n are allocated. RCTs between the groups are also possible in
this setting.
Table 1 Systolic blood pressure in an imaginary adult patient with
anaphylactic shock














Systolic blood pressure of the patient was recovering slowly without
treatments. The patient had an intravenous injection of 0.1 mg
adrenalin at time 10 min
S Systolic blood pressure
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SSTs are also possible in treatment trials of neurode-
generative diseases whose patients almost always show
progressive deteriorations. For example, although RCTs
has not been performed in the levodopa therapy of Par-
kinson’s disease [21], neurologists will admit that symp-
toms lasting for several months of early Parkinson’s
patients almost always improve within a few days after
receiving levodopa.
In preventive medicine, oral rehydration therapy is effective
against diarrhea [22]. RCTs have compared oral rehydration
with intravenous hydration [23]. SSTs can offer the measure-
ment of the effect difference between the treated and the non-
treated in acute stage diarrhea. Because of the necessity of
controlling confounders, SSTs may be restricted within a
narrow set of research topics in preventive medicine. However,
if we have sufficientpast databases of disease incidence and the
derivative of the incidence rate with respect to time is constant,
we may use SSTs for the measurement of effects of exposures
which have a latent period of several years.
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Appendix
The essence of Bayes theorem is as follows. Suppose h is
some quantity that is currently unknown, and let p(h) denote
the prior distribution of h. Suppose we have some observed
evidence y, whose probability of occurrence is assumed to
depend on h. This dependence is formalized by p(y|h), known
as the likelihood. The posterior distribution taking account of
the evidence y is denoted p(h|y). Bayes theorem is
pðhjyÞ / pðyjhÞ  pðhÞ:
The beta distribution is a conjugate family for the
binominal likelihood. This means that a beta prior
distribution and a binominal sample distribution provide
a beta posterior distribution by Bayes theorem.
The mean of Beta(a, b) is aaþb.
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